{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T13:23:49Z","timestamp":1783085029626,"version":"3.54.6"},"reference-count":32,"publisher":"BMJ","issue":"7","license":[{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"unspecified","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015758","name":"Novo Nordisk Pharma","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100015758","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2026,5,19]]},"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Sickle cell disease (SCD) is one of the most common inherited haemoglobinopathies worldwide and the most prevalent monogenic disorder in the UK. Real-world implementation of existing guidance remains variable particularly in emergency and community settings. The study aims to build national consensus among multidisciplinary stakeholders as a crucial first step towards standardising practice and improving outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>\n                      Using a single-round modified Delphi methodology, a Steering Committee of six UK-based specialists identified key domains for discussion and generated 48 consensus statements relevant to the care of patients with SCD. Using a four-point\n                      <jats:italic>Likert<\/jats:italic>\n                      scale, a survey including all statements was disseminated among a wider audience of healthcare professionals (HCPs) to determine agreement. The threshold for agreement was set at \u226575%. Eligible participants for this study included National Health Service (NHS) haematologists (adult or paediatric) and clinical or community nurse specialists from across the UK.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In total, 112 completed surveys were received. Consensus (\u226575% agreement) was achieved for 46 of 48 statements (96%), including 32 (67%) that reached \u226590% agreement. The strongest consensus (&gt;95%) was observed in statements emphasising the need for: broader access to specialist clinics and multidisciplinary care, prioritisation of community-based management and prevention of end-organ damage, education of emergency department staff on acute SCD management and improved HCP understanding of the multisystem nature of SCD and its psychosocial impacts. Two statements (S37, S43) did not meet the threshold, both concerning variability in adherence to national guidelines and allocation of dedicated SCD funding.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>A modified Delphi consensus achieved national multidisciplinary team expert recommendations to optimise NHS SCD care. These recommendations use expert opinion to clarify priorities, identify resource and education gaps, and aim to standardise practice for consistent, high-level patient care and robust outcome assessment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2026-117211","type":"journal-article","created":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T13:04:49Z","timestamp":1783083889000},"page":"e117211","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Single-round modified Delphi consensus to optimise the care of patients with sickle cell disease across multidisciplinary teams within the NHS"],"prefix":"10.1136","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8038-1111","authenticated-orcid":false,"given":"Wale","family":"Atoyebi","sequence":"first","affiliation":[{"name":"Oxford University Hospitals NHS Foundation Trust, Headington, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Velangi","sequence":"additional","affiliation":[{"name":"Birmingham Women\u2019s and Children\u2019s Hospital NHS Foundation Trust, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0513-3331","authenticated-orcid":false,"given":"Kofi A","family":"Anie","sequence":"additional","affiliation":[{"name":"Haematology and Sickle Cell Centre, London North West Healthcare NHS Trust, London, UK"},{"name":"Faculty of Medicine, Imperial College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josef","family":"Huemer","sequence":"additional","affiliation":[{"name":"Moorfields Eye Hospital NHS Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire C","family":"Sharpe","sequence":"additional","affiliation":[{"name":"King\u2019s College Hospital, London, UK"},{"name":"University of Nottingham School of Medicine, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Kesse-Adu","sequence":"additional","affiliation":[{"name":"Guy\u2019s and St Thomas\u2019 NHS Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,7,3]]},"reference":[{"key":"2026070306001911000_16.7.e117211.1","doi-asserted-by":"crossref","DOI":"10.3390\/cells13100848","article-title":"Current and Future Therapeutics for Treating Patients with Sickle Cell Disease","volume":"13","author":"Barak","year":"2024","journal-title":"Cells"},{"key":"2026070306001911000_16.7.e117211.2","doi-asserted-by":"publisher","DOI":"10.1177\/0033354919881438"},{"key":"2026070306001911000_16.7.e117211.3","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-057141","article-title":"Black sickle cell patients\u2019 lives matter: healthcare, long-term shielding and psychological distress during a racialised pandemic in England - a mixed-methods study","volume":"12","author":"Berghs","year":"2022","journal-title":"BMJ Open"},{"key":"2026070306001911000_16.7.e117211.4","unstructured":"Sickle Cell Society . No one\u2019s listening: an inquiry into the avoidable deaths and failures of care for sickle cell patients in secondary care. 2021. Available: https:\/\/www.google.com\/url?sa=t&rct=j&q=&esrc=s&source=web&cd=&cad=rja&uact=8&ved=2ahUKEwjM0870t8eTAxXQUUEAHUqNGggQFnoECAwQAQ&url=https%3A%2F%2Fwww.sicklecellsociety.org%2Fno-ones-listening%2F&usg=AOvVaw0sZCBUuVtKeoMISN42fhME&opi=89978449"},{"key":"2026070306001911000_16.7.e117211.5","unstructured":"Sickle Cell Society and Public Health England . Sickle cell disease in childhood: standards and recommendations for clinical care. 2019. Available: https:\/\/www.google.com\/url?sa=t&rct=j&q=&esrc=s&source=web&cd=&cad=rja&uact=8&ved=2ahUKEwi74ce3uceTAxVzRUEAHaBGHL4QFnoECAwQAQ&url=https%3A%2F%2Fwww.sicklecellsociety.org%2Fpaediatricstandards%2F&usg=AOvVaw39jHs0jH3Qio1l5Jmzam3X&opi=89978449"},{"key":"2026070306001911000_16.7.e117211.6","doi-asserted-by":"crossref","first-page":"4459","DOI":"10.1182\/bloodadvances.2023012467","article-title":"Multicenter, phase 1 study of etavopivat (FT-4202) treatment for up to 12 weeks in patients with sickle cell disease","volume":"8","author":"Saraf","year":"2024","journal-title":"Blood Adv"},{"key":"2026070306001911000_16.7.e117211.7","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1080\/14656566.2024.2317336","article-title":"An update review of new therapies in sickle cell disease: the prospects for drug combinations","volume":"25","author":"Lugthart","year":"2024","journal-title":"Expert Opin Pharmacother"},{"key":"2026070306001911000_16.7.e117211.8","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1002\/cpdd.1058","article-title":"Safety, Pharmacokinetics, and Pharmacodynamics of Etavopivat (FT-4202), an Allosteric Activator of Pyruvate Kinase-R, in Healthy Adults: A Randomized, Placebo-Controlled, Double-Blind, First-in-Human Phase 1 Trial","volume":"11","author":"Forsyth","year":"2022","journal-title":"Clin Pharmacol Drug Dev"},{"key":"2026070306001911000_16.7.e117211.9","unstructured":"Sickle Cell Society . Standards for the clinical care of adults with sickle cell disease in the UK. 2018. Available: https:\/\/www.sicklecellsociety.org\/wp-content\/uploads\/2018\/05\/Standards-for-the-Clinical-Care-of-Adults-with-Sickle-Cell-in-the-UK-2018.pdf"},{"key":"2026070306001911000_16.7.e117211.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2013.12.002"},{"key":"2026070306001911000_16.7.e117211.11","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1004326","article-title":"ACCORD (ACcurate COnsensus Reporting Document): A reporting guideline for consensus methods in biomedicine developed via a modified Delphi","volume":"21","author":"Gattrell","year":"2024","journal-title":"PLoS Med"},{"key":"2026070306001911000_16.7.e117211.12","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26063"},{"key":"2026070306001911000_16.7.e117211.13","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/S2352-3026(23)00118-7","article-title":"Global, regional, and national prevalence and mortality burden of sickle cell disease, 2000\u20132021: a systematic analysis from the Global Burden of Disease Study 2021","volume":"10","author":"Thomson","year":"2023","journal-title":"Lancet Haematol"},{"key":"2026070306001911000_16.7.e117211.14","doi-asserted-by":"crossref","DOI":"10.1186\/s12875-025-02814-0","article-title":"Effects of multidisciplinary teamwork in non-hospital settings on healthcare and patients with chronic conditions: a systematic review and meta-analysis","volume":"26","author":"Shi","year":"2025","journal-title":"BMC Prim Care"},{"key":"2026070306001911000_16.7.e117211.15","doi-asserted-by":"crossref","DOI":"10.1007\/s00431-025-06101-z","article-title":"Challenges in the clinical management of rare diseases and center-based multidisciplinary approach to creating solutions","volume":"184","author":"Gunes","year":"2025","journal-title":"Eur J Pediatr"},{"key":"2026070306001911000_16.7.e117211.16","doi-asserted-by":"crossref","DOI":"10.1186\/s41687-024-00784-y","article-title":"Economic burden and quality of life of caregivers of patients with sickle cell disease in the United Kingdom and France: a cross-sectional study","volume":"8","author":"Besser","year":"2024","journal-title":"J Patient Rep Outcomes"},{"key":"2026070306001911000_16.7.e117211.17","unstructured":"Improvement Analytic Unit (IAU) . Briefing: realising the potential of community-based multidisciplinary teams. 2023. Available: https:\/\/www.google.com\/url?sa=t&rct=j&q=&esrc=s&source=web&cd=&cad=rja&uact=8&ved=2ahUKEwi4pI6Xz8eTAxWeU0EAHRyTHn0QFnoECBsQAQ&url=https%3A%2F%2Fwww.health.org.uk%2Fsites%2Fdefault%2Ffiles%2Fupload%2Fpublications%2F2023%2FMTD%2520briefing_WEB.pdf&usg=AOvVaw0DKtbk6bw6xRwt9DlMtIDl&opi=89978449"},{"key":"2026070306001911000_16.7.e117211.18","unstructured":"NHS England . Primary care service development funding and general practice IT funding guidance 2024\/25, 2024. Available: https:\/\/www.england.nhs.uk\/long-read\/primary-care-service-development-funding-and-general-practice-it-funding-guidance-2024-25"},{"key":"2026070306001911000_16.7.e117211.19","unstructured":"Department of Health and Social Care . Public health ring-fenced grant financial year 2025 to 2026: local authority circular, 2025. Available: https:\/\/www.gov.uk\/government\/publications\/public-health-grants-to-local-authorities-2025-to-2026\/public-health-ring-fenced-grant-financial-year-2025-to-2026-local-authority-circular"},{"key":"2026070306001911000_16.7.e117211.20","unstructured":"Blood Cancer UK . Take action to future-proof the workforce, 2024. Available: https:\/\/bloodcancer.org.uk\/about-us\/our-campaigns\/uk-blood-cancer-action-plan\/take-action-to-future-proof-the-workforce"},{"key":"2026070306001911000_16.7.e117211.21","unstructured":"British Medical Association . Medical staffing in the NHS. 2025. Available: https:\/\/www.bma.org.uk\/advice-and-support\/nhs-delivery-and-workforce\/workforce\/medical-staffing-in-the-nhs"},{"key":"2026070306001911000_16.7.e117211.22","unstructured":"British Society for Haematology . British society for haematology\u2019s advocacy for haematology workforce in the 10-year health plan. 2024. Available: https:\/\/b-s-h.org.uk\/media\/2fjeboen\/brit-soc-for-haematology-change-nhs-response.pdf?cf=638810826719470000"},{"key":"2026070306001911000_16.7.e117211.23","doi-asserted-by":"crossref","first-page":"100026","DOI":"10.1016\/j.rare.2024.100026","article-title":"A unique collaborative model providing supportive and self-advocacy tools to the rare disease community","volume":"2","author":"Harris","year":"2024","journal-title":"Rare"},{"key":"2026070306001911000_16.7.e117211.24","doi-asserted-by":"crossref","DOI":"10.1093\/jscdis\/yoaf011","article-title":"The development of consensus recommendation to improve practice harmonization for Sickle Cell Disease through the National Alliance of Sickle Cell Centers","volume":"2","author":"Kanter","year":"2025","journal-title":"Journal of Sickle Cell Disease"},{"key":"2026070306001911000_16.7.e117211.25","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1080\/17474086.2020.1830370","article-title":"What is the future of patient-reported outcomes in sickle-cell disease?","volume":"13","author":"Singh","year":"2020","journal-title":"Expert Rev Hematol"},{"key":"2026070306001911000_16.7.e117211.26","doi-asserted-by":"crossref","DOI":"10.1093\/jscdis\/yoaf020","article-title":"Identification of hematological biomarkers and assessment of machine learning models for sickle cell anemia severity classification","volume":"2","author":"Ussher","year":"2025","journal-title":"Journal of Sickle Cell Disease"},{"key":"2026070306001911000_16.7.e117211.27","doi-asserted-by":"crossref","first-page":"3821","DOI":"10.1182\/bloodadvances.2025016707","article-title":"Biomarker signatures for sickle cell pain","volume":"9","author":"Gupta","year":"2025","journal-title":"Blood Adv"},{"key":"2026070306001911000_16.7.e117211.28","unstructured":"National Institute for Health and Care Excellence (NICE) . Clinical knowledge summaries (CKS): sickle cell disease. 2025. Available: https:\/\/cks.nice.org.uk\/topics\/sickle-cell-disease"},{"key":"2026070306001911000_16.7.e117211.29","unstructured":"The British Society for Haematology . Guidelines and good practice: sickle cell disease. 2025. Available: https:\/\/cks.nice.org.uk\/topics\/sickle-cell-disease"},{"key":"2026070306001911000_16.7.e117211.30","unstructured":"NHS Race and Health Observatory . Sickle cell digital discovery report: designing better acute painful sickle cell care. 2023. Available: https:\/\/www.nhsrho.org\/wp-content\/uploads\/2024\/05\/Sickle-cell-digital-discovery-report-designing-better-acute-painful-sickle-cell-care-January-2023.pdf"},{"key":"2026070306001911000_16.7.e117211.31","unstructured":"NHS Foundation Trust . Information governance policy and management framework. 2025. Available: https:\/\/www.rdash.nhs.uk\/policies\/information-governance-policy-and-management-framework\/#:~:text=It%20is%20of%20paramount%20importance%20to%20ensure,a%20robust%20governance%20framework%20for%20information%20management"},{"key":"2026070306001911000_16.7.e117211.32","unstructured":"Sickle Cell Society . Sickle cell disease in childhood: standards and recommendations for clinical care 3rd edition. 2019. Available: https:\/\/www.sicklecellsociety.org\/wp-content\/uploads\/2019\/11\/SCD-in-Childhood_Final-version-1.pdf"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2026-117211","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T13:05:25Z","timestamp":1783083925000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2026-117211"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":32,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7,3]]},"published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1136\/bmjopen-2026-117211"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2026-117211","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]}}}